Peptide Knowledge Base · Metabolic
Cagrilintide: what it is, what the evidence says, and its real status
A long-acting amylin analog studied as the satiety layer that amplifies a GLP-1, the canonical 'companion' molecule.
Short version: rarely discussed alone, almost always as the partner that makes a GLP-1 work harder (CagriSema, and the experimental LEAN pairing). Investigational, not approved, not available.
Can you actually get it?
Plain-English verdict: Waitlist / education.
Regulatory status: Investigational (Phase 3) · Not yet approved.
Not available to prescribe. Cagrilintide is an investigational amylin analog (Novo Nordisk) studied mostly in combination (CagriSema). It is not FDA-approved and not compoundable; we educate and capture demand only.
How does Cagrilintide work?
A long-acting analog of amylin, the satiety hormone co-secreted with insulin; it slows gastric emptying and extends fullness, complementing GLP-1 appetite signaling.
What it does — and what it does not do
What it does: Studied as a satiety amplifier that adds to GLP-1 weight effects when combined.
What it does not do: It is not approved, not available, and not typically used alone; combination figures are trial-stage, not promises.
How honest is the evidence?
Evidence grade B — Phase-3 combination data (REDEFINE), re-verify against primary sources. Read our grading methodology for what each grade means.
What we still don't know: Standalone efficacy and long-term safety are less characterized than the combination; the program is ongoing.
WADA status: Not prohibited.
How it is taken
What the literature reports: subcutaneous, weekly. Educational only, no dose figures.
Who should not take it
Investigational, safety not fully characterized; clinician-gated. Class GI tolerability applies in combination.
Sources
REDEFINE / CagriSema Phase-3 program (ongoing, re-verify against primary sources)
Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker or the knowledge base.
Last reviewed 2026-08-11 · Peptós.LIFE · Not medical advice.